Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00527 | 35053008 | Biology (Basel) | The Snoring Index Identifies Risk of Non-Alcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea Syndrome. | 2021 | Details |
| A00528 | 35052873 | Biomedicines | Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00529 | 35052872 | Biomedicines | Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. | 2022 | Details |
| A00530 | 35052859 | Biomedicines | Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies. | 2022 | Details |
| A00531 | 35052840 | Biomedicines | From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. | 2022 | Details |
| A00532 | 35052811 | Biomedicines | Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS). | 2022 | Details |
| A00533 | 35052765 | Biomedicines | Bifidobacterium bifidum Shows More Diversified Ways of Relieving Non-Alcoholic Fatty Liver Compared with Bifidobacterium adolescentis. | 2021 | Details |
| A00534 | 35052763 | Biomedicines | Intestinal Barrier and Permeability in Health, Obesity and NAFLD. | 2021 | Details |
| A00535 | 35052736 | Biomedicines | Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. | 2021 | Details |
| A00536 | 35052726 | Biomedicines | Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. | 2021 | Details |
| A00537 | 35052690 | Biomedicines | Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis. | 2021 | Details |
| A00538 | 35052685 | Biomedicines | Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model. | 2021 | Details |
| A00539 | 35052640 | Antioxidants (Basel) | Phytochemicals from the Cocoa Shell Modulate Mitochondrial Function, Lipid and Glucose Metabolism in Hepatocytes via Activation of FGF21/ERK, AKT, and mTOR Pathways. | 2022 | Details |
| A00540 | 35052597 | Antioxidants (Basel) | Gallic Acid Improves Diabetic Steatosis by Downregulating MicroRNA-34a-5p through Targeting NFE2L2 Expression in High-Fat Diet-Fed db/db Mice. | 2021 | Details |
| A00541 | 35052595 | Antioxidants (Basel) | Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A00542 | 35052590 | Antioxidants (Basel) | Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. | 2021 | Details |
| A00543 | 35052573 | Antioxidants (Basel) | Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig. | 2021 | Details |
| A00544 | 35052547 | Antioxidants (Basel) | Preventive Effects of β-Cryptoxanthin, a Potent Antioxidant and Provitamin A Carotenoid, on Lifestyle-Related Diseases-A Central Focus on Its Effects on Non-Alcoholic Fatty Liver Disease (NAFLD). | 2021 | Details |
| A00545 | 35051649 | Clin Gastroenterol Hepatol | Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. | 2022 | Details |
| A00546 | 35051605 | J Ethnopharmacol | Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A00547 | 35051553 | Mol Cell Endocrinol | Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes. | 2022 | Details |
| A00548 | 35050189 | Metabolites | The Role of Fructose as a Cardiovascular Risk Factor: An Update. | 2022 | Details |
| A00549 | 35050187 | Metabolites | The Interaction between the Gut Microbiome and Bile Acids in Cardiometabolic Diseases. | 2022 | Details |
| A00550 | 35050176 | Metabolites | Lentinan Protects against Nonalcoholic Fatty Liver Disease by Reducing Oxidative Stress and Apoptosis via the PPARα Pathway. | 2022 | Details |
| A00551 | 35048923 | Food Funct | Feeding of cuticles from Tenebrio molitor larvae modulates the gut microbiota and attenuates hepatic steatosis in obese Zucker rats. | 2022 | Details |
| A00552 | 35048297 | J Gen Intern Med | The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care. | 2022 | Details |
| A00553 | 35048271 | Mol Biol Rep | Hepatic microRNA modulation might be an early event to non-alcoholic fatty liver disease development driven by high-fat diet in male mice. | 2022 | Details |
| A00554 | 35048107 | Eur Heart J | Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. | 2022 | Details |
| A00555 | 35047847 | HGG Adv | Identification of 90 NAFLD GWAS loci and establishment of NAFLD PRS and causal role of NAFLD in coronary artery disease. | 2021 | Details |
| A00556 | 35047580 | Front Cardiovasc Med | Alterations of Gut Microbiome and Serum Metabolome in Coronary Artery Disease Patients Complicated With Non-alcoholic Fatty Liver Disease Are Associated With Adverse Cardiovascular Outcomes. | 2022 | Details |
| A00557 | 35047125 | World J Diabetes | Skeletal muscle loss is associated with diabetes in middle-aged and older Chinese men without non-alcoholic fatty liver disease. | 2021 | Details |
| A00558 | 35047114 | World J Diabetes | Thioredoxin interacting protein, a key molecular switch between oxidative stress and sterile inflammation in cellular response. | 2021 | Details |
| A00559 | 35046901 | Front Endocrinol (Lausanne) | The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model. | 2022 | Details |
| A00560 | 35046824 | Front Pharmacol | Limonin Alleviates Non-alcoholic Fatty Liver Disease by Reducing Lipid Accumulation, Suppressing Inflammation and Oxidative Stress. | 2022 | Details |
| A00562 | 35046474 | Sci Rep | Hepatic galectin-3 is associated with lipid droplet area in non-alcoholic steatohepatitis in a new swine model. | 2022 | Details |
| A00563 | 35046340 | Gan To Kagaku Ryoho | [A Case of Nonalcoholic Fatty Liver Disease after Pancreatoduodenectomy Which Reduced Tolerability of Chemotherapy for Postoperative Recurrence]. | 2021 | Details |
| A00564 | 35045647 | Zhonghua Gan Zang Bing Za Zhi | [Research progress of sodium butyrate in metabolic-associated fatty liver disease]. | 2021 | Details |
| A00565 | 35045634 | Zhonghua Gan Zang Bing Za Zhi | [Characteristics of clinical and laboratory indexes in patients with liver disease with positive anti-liver cytosol antibody]. | 2021 | Details |
| A00566 | 35045633 | Zhonghua Gan Zang Bing Za Zhi | [Role and mechanism of miRNA-181a in nonalcoholic fatty liver disease]. | 2021 | Details |
| A00567 | 35045632 | Zhonghua Gan Zang Bing Za Zhi | [Study on plasma Golgi protein 73 and related models in the diagnosis of nonalcoholic fatty liver disease]. | 2021 | Details |
| A00568 | 35045557 | J Pediatr Gastroenterol Nutr | Trends and Disparities in Pediatric Nonalcoholic Fatty Liver Disease-Associated Hospitalizations in the United States. | 2022 | Details |
| A00574 | 35044230 | Antioxid Redox Signal | Inhibition of fatty acid translocase (FAT/CD36) palmitoylation enhances hepatic fatty acid β-oxidation by increasing its localization to mitochondria and interaction with long-chain acyl-CoA synthetase 1. | 2022 | Details |
| A00575 | 35043830 | Sao Paulo Med J | Association between neck circumference and non-alcoholic fatty liver disease: cross-sectional analysis from ELSA-Brasil. | 2022 | Details |
| A00576 | 35043829 | Sao Paulo Med J | High prevalence of functional dyspepsia in nonalcoholic fatty liver disease: a cross-sectional study. | 2022 | Details |
| A00577 | 35042213 | Pathobiology | Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Immunohistochemical Assessment of Markers of Cancer Cell Metabolism. | 2022 | Details |
| A00578 | 35041626 | Am J Gastroenterol | Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00579 | 35041255 | Phytother Res | Activation of PGC-1α via isoliquiritigenin-induced downregulation of miR-138-5p alleviates nonalcoholic fatty liver disease. | 2022 | Details |
| A00580 | 35040788 | Turk J Gastroenterol | Association Between Neutrophil-to-Lymphocyte Ratio with Inflammatory Activity and Fibrosis in Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00581 | 35040549 | Hepatol Res | 2-Step PLT16-AST44 method: Simplified liver fibrosis detection system in patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A00582 | 35040495 | Eur J Clin Invest | Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography. | 2022 | Details |
| A00583 | 35040254 | Chem Biol Drug Des | SU5, a new Auraptene analog with improved metabolic stability, ameliorates nonalcoholic fatty liver disease in methionine- and choline-deficient diet-fed db/db mice. | 2022 | Details |
| A00584 | 35040119 | Eur J Clin Invest | Fatty kidney: A possible future for chronic kidney disease research. | 2022 | Details |
| A00585 | 35040007 | Mol Biol Rep | High-fat diet intake ameliorates the expression of hedgehog signaling pathway in adult rat liver. | 2022 | Details |
| A00586 | 35039476 | Cell Death Dis | Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: recent progress and perspective. | 2022 | Details |
| A00587 | 35038997 | BMC Public Health | Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study. | 2022 | Details |
| A00588 | 35038955 | Bioengineered | MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice. | 2022 | Details |
| A00589 | 35038311 | Eur J Endocrinol | Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. | 2022 | Details |
| A00590 | 35038159 | J Cell Commun Signal | Targeting CCN2 protects against progressive non-alcoholic steatohepatitis in a preclinical model induced by high-fat feeding and type 2 diabetes. | 2022 | Details |
| A00591 | 35036892 | Metabol Open | Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]. | 2022 | Details |
| A00592 | 35036886 | JHEP Rep | Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD. | 2021 | Details |
| A00593 | 35036572 | Biol Methods Protoc | Preparation of fatty acid solutions exerts significant impact on experimental outcomes in cell culture models of lipotoxicity. | 2021 | Details |
| A00594 | 35035690 | Am J Transl Res | Bile acid metabolism and liver fibrosis following treatment with bifid triple viable capsules in nonalcoholic fatty liver disease. | 2021 | Details |
| A00595 | 35035496 | Evid Based Complement Alternat Med | Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway. | 2022 | Details |
| A00596 | 35035396 | Pak J Med Sci | Frequency of non-alcoholic fatty liver disease (NAFLD) and its associated risk factors among Type-2 diabetics. | 2022 | Details |
| A00597 | 35035378 | Front Endocrinol (Lausanne) | Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity. | 2021 | Details |
| A00598 | 35035359 | Front Physiol | Exercise Alleviates the Apolipoprotein A5-Toll-Like Receptor 4 Axis Impairment in Mice With High-Fat Diet-Induced Non-alcoholic Steatohepatitis. | 2021 | Details |
| A00599 | 35034938 | Endocr J | Associations among FT4 level, FT3/FT4 ratio, and non-alcoholic fatty liver disease in Chinese patients with hypopituitarism. | 2022 | Details |
| A00600 | 35034930 | Biol Pharm Bull | Vitexin Attenuates Non-alcoholic Fatty Liver Disease Lipid Accumulation in High Fat-Diet Fed Mice by Activating Autophagy and Reducing Endoplasmic Reticulum Stress in Liver. | 2022 | Details |
| A00601 | 35034646 | Lipids Health Dis | The relationship between Lipocalin-2 level and hepatic steatosis in obese patients with NAFLD after bariatric surgery. | 2022 | Details |
| A00602 | 35034553 | J Med Econ | Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease. | 2022 | Details |
| A00603 | 35033597 | Diabetes Res Clin Pract | Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. | 2022 | Details |
| A00604 | 35033554 | Eur J Pharmacol | Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling. | 2022 | Details |
| A00605 | 35032633 | Clin Gastroenterol Hepatol | Spleen Size Does Not Correlate With Histological Stage of Liver Disease in People With Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00606 | 35032545 | Metabolism | The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials. | 2022 | Details |
| A00607 | 35032488 | Eur J Pharmacol | Dichloroacetate reactivates pyruvate-supported peroxide removal by liver mitochondria and prevents NAFLD aggravation in NAD(P)+ transhydrogenase-null mice consuming a high-fat diet. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A00610 | 35030194 | PLoS One | Mechanisms of liver injury in high fat sugar diet fed mice that lack hepatocyte X-box binding protein 1. | 2022 | Details |
| A00611 | 35029891 | Medicine (Baltimore) | Characteristics of peripheral blood Gamma-glutamyl transferase in different liver diseases. | 2022 | Details |
| A00612 | 35029027 | J Cell Mol Med | Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver disease. | 2022 | Details |
| A00613 | 35028685 | Calcif Tissue Int | Fatty Liver Index and Skeletal Muscle Density. | 2022 | Details |
| A00614 | 35028615 | Cell Rep Med | Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. | 2021 | Details |
| A00615 | 35028346 | Data Brief | Dataset for liver metabolomic profile of highland barley Monascus purpureus went extract-treated golden hamsters with nonalcoholic fatty liver disease. | 2021 | Details |
| A00616 | 35027111 | J Am Coll Cardiol | Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. | 2022 | Details |
| A00617 | 35027066 | Lipids Health Dis | Sex-specific contribution of lipid accumulation product and cardiometabolic index in the identification of nonalcoholic fatty liver disease among Chinese adults. | 2022 | Details |
| A00620 | 35024739 | Rom J Morphol Embryol | Systemic and adipose tissue inflammation in NASH: correlations with histopathological aspects. | 2022 | Details |
| A00621 | 35024735 | Rom J Morphol Embryol | Triglyceride and glucose index: a useful tool for non-alcoholic liver disease assessed by liver biopsy in patients with metabolic syndrome? | 2022 | Details |
| A00622 | 35024313 | Acta Pharm Sin B | Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity. | 2021 | Details |
| A00623 | 35024308 | Acta Pharm Sin B | Proteomics and metabolic phenotyping define principal roles for the aryl hydrocarbon receptor in mouse liver. | 2021 | Details |
| A00624 | 35024184 | J Adv Res | Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. | 2021 | Details |
| A00625 | 35024053 | Cardiovasc Ther | Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes. | 2021 | Details |
| A00626 | 35023936 | Diabetes Metab Syndr Obes | Diagnostic Value of Neutrophil to Lymphocyte Ratio in Non-Alcoholic Fatty Liver Disease Evaluated Using Transient Elastography (TE) with Controlled Attenuated Parameter (CAP). | 2022 | Details |
| A00627 | 35023202 | Hepatology | T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis. | 2022 | Details |
| A00628 | 35023183 | Aliment Pharmacol Ther | NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study. | 2022 | Details |
| A00631 | 35021995 | BMC Gastroenterol | Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population. | 2022 | Details |
| A00632 | 35021598 | Clin Mol Hepatol | Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study. | 2022 | Details |
| A00633 | 35021063 | Cell | Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. | 2022 | Details |
| A00634 | 35021057 | Immunity | Inflammation in obesity, diabetes, and related disorders. | 2022 | Details |
| A00635 | 35020496 | Metab Syndr Relat Disord | Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. | 2022 | Details |
| A00636 | 35020479 | Metab Syndr Relat Disord | Age- and Sex-Specific Differences in Distribution of Cardiometabolic Diseases and Associations of Hand-Grip Strength Indices with Type 2 Diabetes in Korean Adults. | 2022 | Details |
| A00637 | 35019905 | Biomater Sci | Biodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice. | 2022 | Details |